BBOT

BridgeBio Oncology Therapeutics, Inc.
CAPPED RATING

BridgeBio Oncology Therapeutics, Inc. (BBOT) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
B+
Factor Score 3.7 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
F
Factor Score 0.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 4.0
EV / EBITDA 0.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -77.9%
Price Return 12M -84.0%
Catalyst Signal 0.00
Market Cap $158.9M
TTM Revenue N/A
Price / Sales N/A
ROE -46.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B+ (3.7) C- (1.9) C- (2.0) F (0.5) C+ (2.6) C- (2.1)
2026-11-10 A- (3.9) C- (1.9) C (2.2) F (0.6) C+ (2.6) C (2.2)
2026-11-03 B+ (3.7) D+ (1.8) C (2.2) F (0.7) C+ (2.7) C (2.2)
2026-10-27 B+ (3.7) D+ (1.8) C (2.4) F (0.7) C+ (2.6) C (2.2)
2026-10-20 C+ (2.5) D+ (1.8) C (2.4) D- (0.8) C+ (2.6) C- (2.0)
Page 1 of 4